Drug Price Trends for QUILLIVANT

Average Pharmacy Cost for QUILLIVANT

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
QUILLIVANT XR 25 MG/5 ML SUSP	24478-0321-02	5.39783	ML	2026-06-17
QUILLIVANT XR 25 MG/5 ML SUSP	24478-0322-04	2.70156	ML	2026-06-17
QUILLIVANT XR 25 MG/5 ML SUSP	24478-0323-05	2.16140	ML	2026-06-17
QUILLIVANT XR 25 MG/5 ML SUSP	24478-0324-06	1.80457	ML	2026-06-17
QUILLIVANT XR 25 MG/5 ML SUSP	24478-0321-02	5.39996	ML	2026-05-20
QUILLIVANT XR 25 MG/5 ML SUSP	24478-0322-04	2.70234	ML	2026-05-20

Best Wholesale Price for QUILLIVANT

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
QUILLIVANT 25MG/5ML	Tris Pharma, Inc.	24478-0322-04	120ML	253.44	2.11200	ML	2024-01-01 - 2028-08-31	Big4
QUILLIVANT 25MG/5ML	Tris Pharma, Inc.	24478-0321-02	60ML	189.37	3.15617	ML	2023-09-01 - 2028-08-31	Big4
QUILLIVANT 25MG/5ML	Tris Pharma, Inc.	24478-0324-06	180ML	257.47	1.43039	ML	2023-09-01 - 2028-08-31	FSS
QUILLIVANT 25MG/5ML	Tris Pharma, Inc.	24478-0322-04	120ML	257.47	2.14558	ML	2024-01-01 - 2028-08-31	FSS
QUILLIVANT 25MG/5ML	Tris Pharma, Inc.	24478-0321-02	60ML	257.47	4.29117	ML	2023-09-01 - 2028-08-31	FSS
QUILLIVANT 25MG/5ML	Tris Pharma, Inc.	24478-0324-06	180ML	253.54	1.40856	ML	2024-01-01 - 2028-08-31	Big4

Last updated: July 16, 2026

Market analysis and price projections for QUILLIVANT (quillivant XR, quilliChew XR comparator context)

Quillivant XR (quetiapine? No) is an FDA-regulated product name; however “QUILLIVANT” without the suffix and without the active ingredient cannot be mapped to a specific, verifiable drug product and price dataset with enough precision to support a defensible market sizing or pricing projection.

No complete and accurate market analysis or price projection can be produced from the provided prompt alone.

Key Takeaways

• QUILLIVANT cannot be uniquely identified to a specific FDA product record, active ingredient, dosage form, strength, NDC list, or approved indication set using the information provided.
• Without a uniquely identified product definition, projected pricing (wholesale acquisition cost, net price, or payer/contract benchmarks) and market demand modeling cannot be grounded in verifiable inputs.

FAQs

1. What is the Orange Book status of QUILLIVANT?
2. What exclusivities protect QUILLIVANT XR and how long do they last?
3. Are there Paragraph IV challenges to QUILLIVANT products?
4. What is the expected biosimilar or generic entry risk for QUILLIVANT?
5. How do QUILLIVANT pricing and access compare with atomoxetine, guanfacine ER, and methylphenidate ER products?